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Introduction
It is important to remember that traumatic brain injury 
(TBI) is a major cause of death and severe disability 
throughout the world. TBI leads to 1,000,000 hospital 
admissions per annum throughout the European Union. 
It causes the majority of the 50,000 deaths from road traﬃ  c 
accidents and leaves 10,000 patients severely handi capped: 
three quarters of these victims are young people [1]. 
Additionally, TBI causes 290,000 hospital admissions and 
51,000 deaths and leaves 80,000 patients with permanent 
neurological disabilities in the US annually [2]. Th e 
consequence of this is both a devastating emotional and 
physical impact and an enormous ﬁ nancial burden [3].
Th erapeutic hypothermia has been shown to improve 
outcome after cardiac arrest [3], and consequently the 
European Resuscitation Council and American Heart 
Association guidelines [4,5] recommend the use of hypo-
thermia in these patients. Hypothermia is also thought to 
improve neurological outcome after neonatal birth 
asphyxia [6]. Cardiac arrest and neonatal asphyxia patient 
populations present to health care services rapidly and 
without posing a diagnostic dilemma; there fore, thera-
peutic systemic hypothermia may be imple men ted 
relatively quickly. As a result, hypothermia in these two 
populations is similar to the laboratory models wherein 
systemic therapeutic hypothermia is com men ced very 
soon after the injury and has shown so much promise [7].
Th e need for resuscitation and computerised tomo-
graphy (CT) imaging to conﬁ rm the diagnosis in patients 
with TBI is a factor that delays intervention with tem-
pera ture reduction strategies. Treatments in TBI have 
traditionally focussed on restoring and maintaining 
adequate brain perfusion, surgically evacuating large 
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haema tomas where necessary, and preventing or promptly 
treating oedema [3]. Brain swelling can be monitored by 
measuring intracranial pressure (ICP), and in most 
centres ICP is used to guide treatments and to monitor 
their success. Th ere is an absence of evidence for the ﬁ ve 
commonly used treatments for raised ICP and all are 
potential ‘double-edged swords’ with signiﬁ cant dis-
advantages. Th e use of hypothermia in patients with TBI 
may have beneﬁ cial eﬀ ects in both ICP reduction and 
possible neuro-protection.
Pathophysiology
Ischaemia has a key role in all forms of brain injury and 
preventing ischaemic (or secondary) injury is at the core 
of all neuro-protective strategies [3]. A complex cascade 
of processes ensues at the cellular level after a period of 
ischaemia (Table  1), beginning from minutes to hours 
after injury and continuing for up to 72 hours or longer. 
Th us, there may be a window of opportunity of several 
hours, or even days, during which injury can be mitigated 
by treatments such as hypothermia [3].
Early studies that used profound hypothermia in 
models of brain trauma gave inconsistent results. More 
recent studies have shown that moderate/mild hypo-
thermia appears to be neuro-protective in well-charac-
terised rodent models of TBI. Th e eﬀ ects of systemic 
hypothermia (30°C to 36°C) following ﬂ uid percussion 
brain injury in rats were ﬁ rst investigated by Clifton and 
colleagues [8], who showed that hypothermia of 33°C 
reduced mortality rates and attenuated deﬁ cits in motor 
function and weight loss compared with normothermia. 
Dietrich and colleagues [9] showed that post-traumatic 
hypothermia (30°C) initiated 5  minutes after ﬂ uid per-
cussion brain injury reduced overall contusion volume 
Table 1. Possible mechanisms underlying the benefi cial eff ects of hypothermia
Secondary injury Explanation Time frame after injury
Prevention of apoptosisa Ischaemia can induce apoptosis and calpain-mediated proteolysis. This process can be  Hours to days to
 prevented or reduced by hypothermia. even weeks
Reduced mitochondrial  Mitochondrial dysfunction is a frequent occurrence in the hours to days after a period of Hours to days
dysfunction and improved  ischaemia and may be linked to apoptosis. Hypothermia reduces metabolic demands and 
energy homeostasisb may improve mitochondrial function. 
Reduction in free radical  Production of free radicals (for example, superoxide, peroxynitrate, hydrogen peroxide, and Hours to days
productionb hydroxyl radicals) is typical in ischaemia. Mild-moderate (30°C to 35°C) hypothermia is able to 
 reduce this event. 
Mitigation of reperfusion  Cascade of reactions following reperfusion, partly mediated by free radicals but with Hours to days
injuryb distinctive and various features. These are suppressed by hypothermia. 
Reduced permeability of  Blood-brain barrier disruptions induced by trauma or ischaemia are moderated by Hours to days
the blood-brain barrier and  hypothermia. The same eff ect occurs with vascular permeability and capillary leakage. 
the vascular wall and 
reduced oedema formationa  
Reduced permeability of  Decreased leakage of cellular membranes with associated improvements in cell function Hours to days
cellular membranes  and cellular homeostasis, including decrease of intracellular acidosis and mitigation of 
(including membranes of  DNA injury 
the cell nucleus)b  
Improved ion homeostasis Ischaemia induces accumulation of excitatory neurotransmitters such as glutamate and  First minutes to 72 hours
 prolonged excessive infl ux of Ca2+ into the cell. This activates numerous enzyme systems 
 (kinases) and induces a state of hyperexcitability (exitotoxic cascade) that can be moderated 
 by hypothermia. 
Reduced metabolisma Cellular oxygen and glucose requirements are reduced by 5% to 8% per degree Celsius  Hours to days
 decrease in temperature. 
Depression of the immune  Sustained destructive infl ammatory reactions and secretion of pro-infl ammatory cytokines First hour to 5 days
response and various  after ischaemia can be blocked or mitigated by hypothermia. 
potentially harmful 
pro-infl ammatory reactionsa  
Reduction in cerebral  Some areas in the brain have signifi cantly higher temperatures than others. These diff erences Minutes to days
thermopoolinga can increase dramatically after injury with temperatures that are up to 2°C to 3°C higher in 
 injured areas. Hyperthermia can increase the damage to the injured brain cells; this is 
 mitigated by hypothermia. 
Anticoagulant eff ectsa Microthrombus formation may add to brain injury after CPR. Anticoagulant eff ects of  Minutes to days
 hypothermia may prevent thrombus formation. 
Suppression of epileptic  Seizures after ischaemic injury or trauma are common and may add to injury. Hypothermia Hours to days
activity and seizuresa has been shown to mitigate epileptic activity. 
This table summarises potential benefi cial eff ects of hypothermia, based on experimental and clinical studies. aSome supporting evidence. bAnimal studies only. CPR, 
cardiopulmonary resuscitation.
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and preserved survival of the overlying cortical neurons. 
Th erefore, these studies demonstrated that cooling after a 
TBI provided histological/cellular protection, improved 
motor and cognitive function, and reduced mortality. 
Moderate hypothermia (30°C) initiated 5  minutes after 
TBI improved hippocampal-dependent learning and 
memory using the Morris water maze [10]. An important 
predictor of outcome in TBI patients, traumatic axonal 
pathology, is reduced with moderate post-injury hypo-
thermia therapy [11]. Th erefore, post-traumatic hypo-
ther mia modulates the major pathologies in TBI such as 
contusions, neuronal vulnerability, and traumatic axonal 
injury. Mild hypothermia is therefore potentially attrac-
tive as it modulates multiple mechanisms or pathways 
and has advantages over unipolar pharmacological 
attempts to provide neurological protection.
Blood-brain barrier
Alterations in blood-brain barrier (BBB) permeability after 
acute injury result in the crossing of water, electrolytes, 
blood-borne substances, and potential neurotoxic agents 
across the vascular system and into the brain paren-
chyma. Many studies have demonstrated the importance 
of brain and body temperature on the microvascular 
consequences of cerebral ischaemia and trauma. One 
study that assessed the eﬀ ects of intra-ischaemic brain 
temperature (mild hypothermia) on BBB was shown to 
reduce extravasation of the protein tracer horseradish 
peroxidase [12]. Brain water content is signiﬁ cantly 
reduced with hypothermia after focal cerebral ischaemia 
[13,14]. Recent studies have assessed this with magnetic 
resonance imaging and found that reductions in the 
apparent diﬀ usion coeﬃ  cient of water (cellular oedema) 
are also attenuated by hypothermia [15].
In models of post-traumatic injury, hypothermia has 
also been shown to reduce BBB permeability. Hypother-
mia may be attenuating BBB permeability by altering 
matrix metalloproteinases, which are critical extracellular 
enzymes that can disrupt the BBB [16]. Th ese modulating 
eﬀ ects of hypothermia on BBB permeability are impor-
tant beneﬁ cial mechanisms because of the association 
between BBB permeability, formation of vasogenic 
oedema, the extravasation of circulating inﬂ ammatory 
cells and adverse post-injury outcomes.
Infl ammation and oedema
Th e inﬂ ammatory response after TBI is signiﬁ cantly 
modulated by hypothermia in laboratory and clinical 
studies. As well as attenuating the increase in BBB 
permeability and leucocyte margination, the endogenous 
inﬂ ammatory response of the central nervous system 
(CNS) is reduced by hypothermia. Astrocytes and 
micro glia respond to CNS injury by proliferating 
around the injury areas and releasing pro-inﬂ ammatory 
communi cation molecules as an endogenous repair 
mechanism. Hypothermia signiﬁ cantly attenuates the 
activation of both astrocytes and microglia [17-20]. 
Combination therapy including the anti-inﬂ ammatory 
cytokine inter leukin-10 and hypothermia therapy was 
attempted in both TBI and focal cerebral ischaemia [21]. 
Synergistic eﬀ ects were seen in focal cerebral ischaemia 
but not in TBI, suggesting that the cellular biology of 
inﬂ ammation in these two major CNS injuries has an 
inﬂ uence on the eﬀ ect of subsequent hypothermia. 
Another major aspect of the inﬂ ammatory response to 
CNS injury is the release of reactive oxygen species by 
astrocytes and microglia. Hypothermia reduces increases 
in tissue levels of superoxide, nitric oxide, and the 
hydroxyl radical [22,23]. Superoxide dismutase, the 
enzyme responsible for scavenging superoxide, is 
increased by hypothermia [24,25], and the enzyme 
responsible for synthesising nitric oxide, nitric oxide 
synthase, is attenuated by hypo thermia [26].
Metabolism
Exploiting local measures of glucose metabolism using 
2-deoxyglucose techniques, researchers showed that 
moderate hypothermia (30°C) reduced glucose utilisation 
compared with normothermia [27]. Metabolic eﬀ ects of 
mild hypothermia have also been shown using nuclear 
magnetic resonance spectroscopy, in which the metabolic 
eﬀ ects of diﬀ erent levels of hypothermia were reported 
[28]. Th erefore, hypothermia lowers metabolic and energy 
demands, having potentially beneﬁ cial eﬀ ects on cyto-
plasmic ATP and the maintenance of normal trans-
membrane ion and neurotransmitter gradients. Th e 
magnitude of preservation of ATP levels depends on both 
the temperature reduction and the severity of the injury. 
Th erefore, an important mechanism for the neuro-
protective eﬀ ects of hypothermia is a reduction or delay in 
metabolic demand during and after an acute CNS injury.
Excitotoxicity
Th e eﬀ ects of moderate hypothermia on glutamate 
excito toxicity were reported using microdialysis to assay 
extracellular/extravascular concentrations of neurotrans-
mitters after global ischaemia. Th e middle cerebral artery 
occlusion model is considered a reasonable model for 
traumatic hemorrhagic contusion (John Povlishock, 
personal communi cation). Busto and colleagues [22] 
showed that intra-ischaemic hypothermia (33°C and 
30°C) attenuated the rise in extracellular levels of 
glutamate and dopamine after global cerebral ischaemia. 
Th ese studies have been replicated in a variety of models 
of ischaemia, indicating that one of the major 
mechanisms by which temperature aﬀ ects neuronal 
vulnerability is through reducing excito toxicity following 
cerebral ischaemia [22,29,30]. Delayed pharmacological 
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treatments that reduce excitotoxicity further improve 
outcome in combination with hypo thermia [31] and may 
be a promising strategy for further studies. Th e glutama-
tergic receptors, AMPA (alpha-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate) and NMDA (N-methyl 
d-aspartate), are also modulated by hypothermia. 
Expression of hippocampal glutamate receptors is 
decreased after transient global ischaemia and this is 
completely blocked by intra-ischaemic hypothermia [32].
Other neurotransmitters are also modulated by hypo-
ther mia. Lyeth and colleagues [33] demonstrated that 
hypothermia (30°C) reduced elevations in cerebrospinal 
levels of acetylcholine after TBI. Conversely, hypothermia 
delayed decreases in dopamine, norepinephrine, and 
serotonin after global cerebral ischaemia [34]. But other 
studies have demonstrated that hypothermia (32°C) can 
improve outcome after CNS injury without attenuating 
extracellular levels of glutamate and aspartate [11,28,35]. 
Th e neurotransmitter response, in various injury models, 
may be temperature-dependent, but attenuating other 
injury cascades may be more important in delivering 
possible beneﬁ cial eﬀ ects of hypothermia.
Cerebrovascular eff ects
Th e eﬀ ects of hypothermia on cerebral blood ﬂ ow are 
controversial. In 1954, Rosomoﬀ  and Holaday [36] 
demon strated that systemic hypothermia to 25°C signi ﬁ -
cantly lowered cerebral blood ﬂ ow. However, in a model 
of selective brain cooling (30°C), cortical blood ﬂ ow 
measured by laser Doppler ﬂ owmetry was shown to 
increase above control levels [37]. Cerebrovascular 
changes secondary to cooling the brain are important 
because reductions in blood ﬂ ow to critical levels could 
have adverse eﬀ ects on tissue survival and functional 
outcome.
Intracellular calcium-dependent signalling
Th ere are pronounced changes in calcium-dependent 
intra cellular signalling pathways after CNS injury. 
Normal neuronal activity is mediated by signalling 
through protein kinases and several of these have been 
documented to be disrupted by TBI and cerebral 
ischaemia. Temporary cerebral ischaemia inhibits the 
activity of calcium/calmodulin-dependent protein kinase 
II (CaMKII), a key protein kinase that mediates synaptic 
strength and this is attenuated by hypothermia [38]. 
Protein kinase C (PKC) translocates to the membrane 
after cerebral ischaemia and undergoes inhibition; hypo-
thermia rescues the inhibition of PKC activity and its 
translocation to the membrane [39]. Recently, various 
transcription factors that participate in normal neuronal 
functioning have been shown to be sensitive to tem-
perature. Th e immediate early gene c-Fos, which regulates 
key genetic responses of neurons, is activated by 
hypothermia after transient global ischaemia [17,40,41]. 
Th ese studies underline that tem pera ture may have 
profound eﬀ ects on events associated with neuronal 
injury as well as the normal processing of neuronal 
signals throughout brain circuits.
Neuronal cell death
Although neuronal necrosis is commonly seen in most 
CNS injury models, evidence for apoptotic cell death has 
also been documented using various histochemical and 
molecular techniques. As with necrosis, apoptotic cell 
death appears to be sensitive to post-injury hypothermic 
treatment strategies. Recent studies indicate that apop-
totic cell death is another important target by which 
temperature may aﬀ ect long-term outcome in various 
models of CNS injury. Various gene families (genes with 
a similar sequence of DNA nucleotides) have been shown 
to be sensitive to post-injury temperature manipulations 
in models of ischaemia and trauma [42]. Th e ability of 
post-injury temperature to aﬀ ect the acute and more 
delayed genetic response to injury is important in that 
these genes may be important in determining the cellular 
response or responses that result in secondary injury. 
Genomic studies using high-throughput screening and 
bioinformatics are ongoing in many laboratories and 
these contemporary technologies will help to determine 
how hypothermia may protect and potentially repair 
CNS tissues after injury.
Systematic review and meta-analysis have not been 
rigorously applied to TBI models. Such an approach is 
beyond the scope of this paper but in the future would 
enhance translational research and (hopefully) reduce 
futile studies. Th e CAMARADES (Collaborative Approach 
to Meta Analysis and Review of Animal Data from 
Experimental Stroke) group have successfully applied 
such methodology to stroke models [43].
Th erefore (with the proviso above), numerous animal 
experiments, in diﬀ erent species, have shown that 
induced hypothermia improves outcome after experi-
mental TBI. Th is has led to the undertaking of a large 
number of clinical trials [3]. Interpretation of these 
results is complicated by the fact that these studies have 
enrolled diﬀ erent categories of patients, with diﬀ erent 
types of injuries, and have used widely diverging 
treatment protocols [44]. Most have used elevated ICP as 
an inclusion criterion although some have used a CT 
scan criterion. Th e duration of cooling has varied from 
24 hours to more than 5 days, and re-warming rates have 
also varied. Some studies have used ICP to guide depth 
and duration of treatment, although responses to 
rebound intracranial hypertension have diﬀ ered [3]. Co-
interventions such as osmotic therapy, sedation, anal-
gesia, paralysis, and targets for mean arterial pressure 
and cerebral perfusion pressure have also varied 
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considerably [3]. All of these factors can aﬀ ect outcome 
after TBI in general and the potential eﬃ  cacy of cooling 
in particular. Th us, interpreting, comparing, and 
aggregating the results of these studies present a number 
of complex challenges.
Review of clinical evidence
Th ere have been eight meta-analyses carried out on this 
subject from the years 2002 to 2009. Th is section is a 
literature review of the available evidence. In total, 29 
clinical studies have been performed to assess the eﬀ ects 
of hypothermia in TBI. Twenty-seven of these were 
performed in adult patients, and 18 of these 27 included 
control groups. Data from one pilot study were 
subsequently included in a larger study, therefore leaving 
17 studies. As outlined above, study protocols have 
diﬀ ered considerably, and not all studies were (properly) 
randomised [3]. A total of 131 patients were enrolled into 
two studies undertaken in patients with normal ICP. Only 
one of these studies reported outcome data (at 3 months) 
and the results showed no signiﬁ cant diﬀ erence between 
groups (good outcome in 21/45 [hypothermia] versus 
27/46 patients [controls], P = 0.251) [45].
Eighteen studies, with outcome data available for 2,096 
patients, used hypothermia in patients with high ICP that 
was refractory to ‘conventional’ treatments (usually 
sedation/analgesia, paralysis, osmotic therapy, and some-
times barbiturates) [46-61]. All observed decreases in 
ICP during cooling. Th irteen of these studies reported 
signiﬁ cant improvements in outcome associated with 
hypothermia [45,49-51,53,54,56-60,62,63]. All of these 
were performed in specialised neurotrauma centres with 
experience in applying hypothermia and managing its 
side eﬀ ects. Ten were single-centre studies [47,49,51,53,5
4,57,59,60,62,63], and three (all performed in China) 
[51,62,63] were multi-centre. Four additional studies 
[48,52,55,58] observed a trend to improved outcome, but 
these diﬀ erences were not statistically signiﬁ cant.
In contrast, one of the two largest multi-centre 
randomised controlled trials (RCTs) failed to show that 
induced hypothermia improved outcome at 6  months 
after TBI (relative risk [RR] of a poor outcome 1; 95% 
conﬁ dence interval [CI] 0.8 to 1.2; P = 0.99) [46]. Signiﬁ -
cantly more of the patients admitted to hospital with 
hypothermia who were randomly assigned to normo-
thermia, and consequently re-warmed, had a poor 
outcome (78%, n = 31) compared with patients admitted 
with hypothermia and treated with hypothermia (61%, 
n = 38) (P = 0.09).
On subsequent analysis, it became clear that although 
this study was methodologically well designed, there was 
marked inter-centre variance in the treatment eﬀ ect of 
hypothermia, age of participants, severity of illness 
scoring between groups, management of intracranial 
hypertension, and haemodynamic and ﬂ uid management 
[64]. Induced hypothermia in the hypothermia group was 
started relatively late with a slow speed of cooling 
(average time to target temperature of more than 8 hours) 
in all centres.
Hypotension (lasting more than 2  hours) and hypo-
volaemia occurred three times more frequently in the 
hypothermia group. Bradycardia associated with hypo-
tension occurred four times more frequently in this 
group, and electrolyte disorders and hyperglycaemia 
were also found more frequently in the hypothermia 
group [46]. All of these complications are known side 
eﬀ ects of hypothermia. Most are easily preventable with 
good intensive care and should not be regarded as 
inevitable consequences of hypothermia treatment. Since 
even very brief episodes of hypotension or hypovolaemia 
can adversely aﬀ ect outcome in TBI, these and other 
issues may have signiﬁ cantly aﬀ ected the results of this 
trial [65-67]. One possible problem was that some of the 
participating centres had little or no previous experience 
in using hypothermia. Large centres familiar with cooling 
showed apparently favourable neurological outcomes 
whereas smaller centres showed poor outcomes.
Induction of hypothermia
Th e most widely accepted use of hypothermia is after 
cardiac arrest. Two RCTs in this patient group have 
shown signiﬁ cant neurological improvements in patients 
who were treated with hypothermia many hours after 
injury and whose initial cardiac rhythm was ventricular 
ﬁ brillation or ventricular tachycardia [68,69]. Subsequent 
data from a large study of patients after myocardial 
infarc tion suggest that infarct size was reduced in 
patients who were cooled to less than 35°C before 
coronary intervention [70], thus suggesting that faster 
cooling rates may be beneﬁ cial to patient outcome.
Methods of cooling can be broadly divided into surface 
and core cooling techniques [71]. Th e above study used 
surface cooling devices alone and found that large 
numbers of patients did not reach the target temperature 
quickly enough before the start of the coronary inter-
vention [70]. Despite advancing technology in surface 
cooling devices and the introduction of endovascular 
catheters for core cooling, average periods of 2 to 3 hours 
are still required to reach temperatures of 32°C to 34°C 
[71]. Th e currently available surface cooling devices are 
also relatively large and cumbersome. Th is coupled with 
the need for staﬀ  with specialist knowledge of the 
management of induced hypothermia may prevent its use 
outside of the intensive care unit [71].
A recent study examined the feasibility, speed, and 
complication rates of infusing refrigerated ﬂ uids intra-
venously to quickly induce hypothermia in patients with 
various neurological injuries [71]. Results showed that a 
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1,500 mL infusion of 0.9% saline, administered over the 
course of 30  minutes in patients without cardiogenic 
shock, reduced core temperature from 36.9°C ± 1.9°C to 
34.6°C  ±  1.5°C at 30  minutes and to 32.9°C  ±  0.9°C at 
60  minutes. Continuous monitoring of arterial blood 
pressure, heart rhythm, central venous pressure, arterial 
blood gasses, and serum levels of electrolytes, platelets, 
and white blood cells showed no signiﬁ cant adverse 
events [71].
When hypothermia develops, the body will imme diately 
try to counteract the temperature drop to maintain 
homeostasis [72]. One of the key mechanisms of heat 
production is shivering, which can lead to an increased 
oxygen consumption of 40% to 100%, which may be 
detrimental in this patient population. Sedation drugs are 
known to increase peripheral blood ﬂ ow and, in turn, 
increase the transfer of heat from the core to the 
peripheries, thus reducing core temperature [72]. 
Th erefore, shivering may be counteracted by the adminis-
tration of sedatives, anaesthetic agents, opiates, and/or 
paralysing agents [72].
It should be noted, however, that the capacity and 
eﬀ ectiveness of the mechanisms of controlling body 
temperature decrease with age. Younger patients will 
there fore react earlier and with greater intensity than 
older patients. For this reason, induction of hypo-
thermia in younger patients often requires high doses of 
sedation drugs to neutralise the counter-regulatory 
mechanisms [72].
Meta-analyses
Eight meta-analyses have been published between the 
years 2000 and 2009 [73-80]. Th ese include various 
numbers of trials, with varying quality of randomisation 
and blinding procedures. All have found a trend to 
positive eﬀ ects of hypothermia on neurological outcome, 
although statistical signiﬁ cance was reached in only two 
reviews: RR of improved neurological outcome of 0.78 
(95% CI 0.63 to 0.98) [73] and RR of 0.68 (95% CI 0.52 to 
0.89) [74]. Since submission of this manuscript, two 
Cochrane systematic reviews (issue 1 [79] and updated 
issue 2 [80] from 2009) have been published (Figure  1). 
Th e authors found that hypothermia may be eﬀ ective in 
reducing death and unfavourable outcomes, but 
signiﬁ cant beneﬁ t was found only in low-quality trials. 
Th e high-quality trials found some non-signiﬁ cant 
beneﬁ t of hypothermia.
Th e meta-analysis of Peterson and colleagues [78] 
included eight trials that studied comparable patient 
groups at baseline. Hypothermia was shown to reduce 
mortality by 20%, although this was not statistically 
signiﬁ cant (RR 0.80, 95% CI 0.59 to 1.09). Subgroup 
analysis showed that this eﬀ ect was signiﬁ cantly greatest 
when hypothermia was maintained for more than 48 hours 
(RR 0.51, 95% CI 0.33 to 0.79). Hypothermia was also 
associated with a non-signiﬁ cant increase of 25% in 
neurological outcome when measured by the Glasgow 
Outcome Scale at 6 months (RR 1.25, 95% CI 0.96 to 1.62). 
Despite not reaching statistical signiﬁ cance, results 
showed an increased likelihood of improved neurological 
outcome when cooling was maintained for more than 
48  hours (RR 1.91, 95% CI 1.28 to 2.85). Another key 
ﬁ nding of this meta-analysis is that hypothermia was of 
signiﬁ cant beneﬁ t only to those patients who had not 
received barbiturate therapy (RR 0.58, 95% CI 0.40 to 0.85).
A criticism of these analyses is that most failed to take 
account of important diﬀ erences in patient groups (such 
as those with or without intracranial hypertension) and 
of diﬀ erences in treatment protocols, except the use of 
hypothermia. Only one diﬀ erentiated between studies 
that enrolled patients with normal ICP and those that 
enrolled patients with intracranial hypertension and that 
analysis found no neurological improve ment associated 
with hypothermia [77]. Only two assessed eﬀ ects of 
treatment duration and speed of re-warming [73,74], 
concluding that cooling for more than 48 hours and re-
warming rates of 24  hours, or 1°C/4  hours, were key 
factors in reducing mortality (RR 0.70, 95% CI 0.56 to 
0.87) and improving neurological outcome (RR 0.79, 95% 
CI 0.63 to 0.98), respectively.
In summary, the evidence from previous research 
shows that induced hypothermia may be eﬀ ective in 
patients with severe TBI and intracranial hypertension 
provided that the treatment is continued for long enough 
(between 48 hours and 5 days) and that patients are re-
warmed slowly (1°C/4  hours). Experience with cooling 
also appears to be important if complications that may 
outweigh the beneﬁ ts of hypothermia are to be avoided.
Rationale for Eurotherm3235Trial
Th e Eurotherm3235Trial will enrol TBI patients who have 
an ICP of more than 20 mm Hg for at least 5 minutes after 
ﬁ rst-line treatments with no obvious reversible cause (for 
example, patient position, coughing, or inadequate 
sedation). Th ree stages of TBI management have been 
developed to support the trial and are based upon the 
best evidence available (Figure  2) [73,81]. Th e Brain 
Trauma Foundation’s recommended treatment threshold 
for treatment of ICP is 20 mm Hg [73]. Although early 
cooling after injury is considered to be beneﬁ cial, this is 
oﬀ set by the failure to show beneﬁ t from hypothermia in 
the absence of raised ICP. Enrolment to the 
Eurotherm3235Trial will therefore be allowed for up to 
72 hours following injury. Th is potential delay in cooling 
will be compensated for, to an extent, by inducing 
hypothermia with 20 to 30  mL/kg of refrigerated 0.9% 
saline given intravenously over the course of 30 minutes. 
No maximum duration of cooling is speciﬁ ed, and 
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Figure 1. Hypothermia for traumatic brain injury. Immediate hypothermia is compared with normothermia. The outcome was death at 
fi nal follow-up stratifi ed by trial quality. CI, confi dence interval; M-H, Mantel-Haenszel. Reproduced with permission from [80]. Copyright 2009, 
The Cochrane Collaboration.
Figure 2. Stages of therapeutic management after traumatic brain injury. These ‘stages’ have been developed for use in the 
Eurotherm3235Trial using evidence synthesis from the Brain Trauma Foundation [73] and the European Brain Injury Consortium [81]. 
CSF, cerebrospinal fl uid; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen.
STAGE 2
Mannitol (maintain serum
osmolarity <315 mosmoles)
Hypertonic Saline (avoid in
hyponatraemic patients,
caution in patients with
cardiac or pulmonary
problems)
Inotropes to maintain
cerebral perfusion pressure
(CPP) 60 mmHg
Monitor blood Magnesium
levels and replace as
required
Barbiturates not
permitted
± induced hypothermia
STAGE 1
Admission to the Intensive
Care Unit (ICU)
Ventilation PaO2  11 kpa
PaCO2 4.5-5.0 kpa
Sedation
Analgesia ± paralysis
30º head of bed elevation
Intravenous fluids ±
inotropes to maintain mean
arterial pressure (MAP)
80 mmHg
Ventriculostomy ± CSF
drainage
Surgical removal of space
occupying lesions
± prophylactic
anticonvulsants
STAGE 3
Barbiturate therapy
Decompressive
Craniectomy
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hypothermia will continue until ICP is no longer 
dependent on temperature reduction to remain below 
20 mm Hg. Patients will then be slowly re-warmed at a 
rate of 0.25°C per hour (1°C/4 hours).
Th e experience from previous hypothermia trials 
underscores the potential diﬃ  culties in using therapeutic 
hypothermia treatment for TBI. For this reason, and to 
reduce inter-centre variance, only centres experienced 
with the care of TBI patients and the use of hypothermia 
(after either cardiac arrest or TBI) will be initiated.
Conclusions
Many potential neuro-protective pharmacological inter-
ventions have been tested and have failed to show beneﬁ t 
in TBI. Common reasons that have been cited include 
inadequate or low methodological quality preclinical 
studies and poor (and often underpowered) clinical study 
design. Hypothermia has extensive preclinical data 
supporting clinical testing and generally meets the STAIR 
(Stroke Th erapy Academic Industry Roundtable) recom-
mendations [80]. Th e Eurotherm3235Trial will recruit 
1,800 patients in 41 months and will be one of the largest 
TBI studies to date.
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